Orbimed Advisors LLC Buys 16,096 Shares of Vera Therapeutics, Inc. $VERA

Orbimed Advisors LLC increased its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 4.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 369,596 shares of the company’s stock after purchasing an additional 16,096 shares during the period. Orbimed Advisors LLC owned approximately 0.51% of Vera Therapeutics worth $14,869,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its holdings in Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in Vera Therapeutics during the 4th quarter valued at $46,000. Quantbot Technologies LP purchased a new stake in Vera Therapeutics during the 2nd quarter valued at $51,000. Aster Capital Management DIFC Ltd purchased a new stake in Vera Therapeutics during the 4th quarter valued at $71,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after buying an additional 2,757 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Price Performance

VERA opened at $35.45 on Monday. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a 1-year low of $19.07 and a 1-year high of $56.05. The company has a market capitalization of $2.54 billion, a PE ratio of -6.40 and a beta of 0.92. The firm’s 50 day simple moving average is $37.00 and its two-hundred day simple moving average is $40.09.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period last year, the firm posted ($0.81) EPS. As a group, equities analysts forecast that Vera Therapeutics, Inc. will post -6.37 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on VERA. Guggenheim raised their price target on Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. TD Cowen increased their target price on Vera Therapeutics from $73.00 to $78.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Needham & Company LLC set a $125.00 target price on Vera Therapeutics in a research report on Wednesday, July 8th. Finally, Bank of America boosted their price target on Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $84.58.

Insider Buying and Selling

In related news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the transaction, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 83,250 shares of company stock valued at $3,337,770. 15.90% of the stock is currently owned by company insiders.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.